Abstract
Oxidation of LDL (oxLDL) is a crucial step in the development of cardiovascular disease. Treatment with antibodies directed against oxLDL can reduce atherosclerosis in rodent models through unknown mechanisms. We demonstrate that through a novel mechanism of immune complex formation and Fc-γ receptor (FcγR) engagement, antibodies targeting oxLDL (MLDL1278a) are anti-inflammatory on innate immune cells via modulation of Syk, p38 MAPK phosphorylation and NFκB activity. Subsequent administration of MLDL1278a in diet-induced obese (DIO) nonhuman primates (NHP) resulted in a significant decrease in pro-inflammatory cytokines and improved overall immune cell function. Importantly, MLDL1278a treatment improved insulin sensitivity independent of body weight change. This study demonstrates a novel mechanism by which an anti-oxLDL antibody improves immune function and insulin sensitivity independent of internalization of oxLDL. This identifies MLDL1278a as a potential therapy for reducing vascular inflammation in diabetic conditions.
Original language | English (US) |
---|---|
Pages (from-to) | 256-269 |
Number of pages | 14 |
Journal | Molecular Metabolism |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - Aug 2013 |
Keywords
- Atherosclerosis
- Diabetes
- Inflammation
- Nonhuman primate
- Obesity
- Ox-LDL
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology